Collaboration and License Agreements - Additional Information (Details)							1 Months Ended								3 Months Ended				6 Months Ended	12 Months Ended
	Mar. 25, 2021 USD ($) $ / shares	Feb. 14, 2021 USD ($) Program	Feb. 14, 2021 USD ($)	Apr. 29, 2020 USD ($) Unit $ / shares shares	May 31, 2018 USD ($)	Oct. 31, 2017 shares	Jul. 31, 2022 USD ($)	Jun. 30, 2020 USD ($)	Mar. 31, 2020 USD ($) shares	Aug. 31, 2019 USD ($)	Sep. 30, 2018 USD ($) Antibodies	Jul. 31, 2018 USD ($) Product	May 31, 2018 USD ($) Program	Oct. 31, 2017 USD ($) shares	Jun. 30, 2021 USD ($)	Mar. 31, 2021 shares	Jun. 30, 2020 USD ($)	Mar. 31, 2020 USD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	May 27, 2022 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Value of shares agreed to purchase																						$ 323,214,000
Profit sharing amount constrained																				$ (369,678,000)	$ 0
Deferred revenue, noncurrent																				53,207,000	3,815,000
Cost of revenue																				146,319,000	65,865,000	0
Receivable from collaboration																				0	773,079,000
Contract Revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues from contract with customers																				52,714,000	169,874,000	44,498,000
License
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues from contract with customers																				22,289,000	0	22,747,000
Collaboration Revenue [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues from contract with customers																				1,505,469,000	917,194,000	0
2020 GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Profit sharing amount constrained																				(369,700,000)
2021 GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Reclassified deferred revenue																				51,700,000
Deferred revenue, noncurrent																				$ 51,700,000
Brii Bio | Development Programs Exercised by Brii | VIR-3434
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Range of royalty payment to be received							mid-teens to mid-twenties
2020 Stock Purchase Agreement | 2020 GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of common stock, shares | shares				6,626,027
Share purchase price per share | $ / shares				$ 37.73
Value of shares agreed to purchase				$ 250,000,000.0
Preliminary Collaboration Agreement | 2020 GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of years conduct certain research and development activities under mutually agreed development plans				4 years
Maximum percentage of right to perform details in connection with antibody product				20.00%
Termination description																				Either party has the right to terminate the 2020 GSK Agreement in the case of the insolvency of the other party, an uncured material breach of the other party with respect to a collaboration program or collaboration product, or as mutually agreed by the parties.
Number of units of account | Unit				4
Research and development expense																				$ 31,400,000	77,300,000	25,400,000
Collaboration type and program								The collaboration initially focused on the development and commercialization of three types of collaboration products under three programs: (1) antibodies targeting SARS-CoV-2 and potentially other coronaviruses (the “Antibody Program”); (2) vaccines targeting SARS-CoV-2 and potentially other coronaviruses (the “Vaccine Program”), and (3) products based on genome-wide CRISPR screening of host targets expressed in connection with exposure to SARS-CoV-2 and potentially other coronaviruses (the “Functional Genomics Program”)
Preliminary Collaboration Agreement | 2020 GSK | Antibody Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Percentage of development costs				72.50%
Antibody license transaction price				$ 43,300,000
Revenues from contract with customers																	$ 43,300,000
Preliminary Collaboration Agreement | 2020 GSK | Vaccine Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Percentage of development costs				27.50%
Preliminary Collaboration Agreement | 2021 GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of separate programs | Program		3
Upfront payment received		$ 225,000,000.0	$ 225,000,000.0
Option exercise fee to be received		300,000,000.0	300,000,000.0
Preliminary Collaboration Agreement | 2021 GSK | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Pre Defined Regulatory Milestone Consideration To Be Received		$ 200,000,000.0	200,000,000.0
2020 Preliminary Collaboration Agreement and Stock Purchase Agreement | GGL | ASC 606
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Fair market value of the common stock issued				$ 206,700,000
Common stock price per share | $ / shares				$ 36.70
Premium received on sale price of common stock				$ 43,300,000
Amendment Number One Member | 2020 GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received																							$ 7,000,000.0
Contract revenue																				7,000,000.0
2021 Stock Purchase Agreement | GGL
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of common stock, shares | shares																1,924,927
Value of shares agreed to purchase			$ 120,000,000.0
2021 Preliminary Collaboration Agreement and Stock Purchase Agreement | GGL | ASC 606
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Fair market value of the common stock issued	$ 85,200,000
Common stock price per share | $ / shares	$ 52.70
Premium received on sale price of common stock	$ 34,800,000
2021 GSK Collaboration
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of years conduct certain research and development activities under mutually agreed development plans			3 years
Percentage of share development costs		50.00%
Percentage of share Profit and loss		50.00%
2020 GSK Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Receivable from collaboration																					773,100,000
2021 GSK Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Premium received on sale price of common stock		$ 34,800,000
Research and development expense																				2,300,000	500,000
Upfront fee			$ 225,000,000.0
Collaboration Agreement Transaction Price Consideration			$ 259,800,000
2021 GSK Agreement | Contract Revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues from contract with customers															$ 168,300,000
2021 GSK Agreement | GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Transaction Price Upon Option Exercise																				39,800,000
Contract with Customer, Liability, Revenue Recognized																				39,800
Brii Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Termination description					Each party may terminate for convenience all rights and obligations with respect to any program for which it has an option, with 30 days’ written notice (if the terminating party has not exercised an option for such program) or 180 days’ notice (following the exercise of an option for such program). The Brii Agreement may also be terminated by either party for insolvency of the other party, and either party may terminate the Brii Agreement in its entirety or on a program-by-program basis for the other party’s uncured material breach on 60 days’ written notice (or 30 days’ notice following failure to make payment).
Written notice period to terminate licensed program for uncured material breach													60 days
Written notice to terminate licensed program if exercise													180 days
Written notice to terminate licensed program if not exercise													30 days
Written notice period to terminate licensed program for failure to make payment													30 days
Brii Agreement | Development Programs Exercised by Vir
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Option exercise fee, low end of the range					low tens of millions
Regulatory milestone payment on licensed product, low end of the range													low tens of millions
Regulatory milestone payment on licensed product, high end of the range					$ 100,000,000.0								$ 100,000,000.0
Option exercise fee, high end of the range					50,000,000.0								50,000,000.0
Maximum Aggregate Sales Milestone Payments													$ 175,000,000.0
Brii Agreement | Development Programs Exercised by Brii
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Range of royalty payment to be received								high-teens to high-twenties
Regulatory milestone payment to be received								$ 30,000,000.0
Maximum Sales Milestone Payment To Be Received								175,000,000.0									175,000,000.0		$ 175,000,000.0
Option exercise fee, low end of the range													mid-single-digit millions
Regulatory milestone payment on licensed product, low end of the range													mid-single-digit millions
Regulatory milestone payment on licensed product, high end of the range					30,000,000.0								$ 30,000,000.0
Option exercise fee, high end of the range					$ 20,000,000.0								20,000,000.0
Maximum Aggregate Sales Milestone Payments													$ 175,000,000.0
Brii Agreement | Development Programs Exercised by Brii | VIR-3434
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Option exercise fee received							$ 20,000,000.0
Brii Agreement | Brii Bio Parent
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment to collaborator resulting from program option exercise																			10,000,000.0
Maximum number of development program granted from Vir to Brii | Program | Program													4
Maximum number of development program granted from Brii to Vir | Program | Program													4
Percentage of ordinary share equal to outstanding share													9.90%
Carrying value of investment at cost															$ 5,700,000
Option exercise fee received								20,000,000.0
Brii Agreement | Brii Bio Parent | VIR-3434
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue								2,300,000									2,300,000		$ 2,300,000
Options Transaction Price								$ 22,300,000
Brii Agreement | Brii Bio Parent | License
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue from Related Parties																				22,300,000	$ 0	22,700,000
Payment to collaborator resulting from program option exercise																						10,000,000.0
Brii Agreement | Brii Bio Parent | Vir 2218
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue							2,700,000
Options Transaction Price							22,700,000
Option exercise fee received							20,000,000.0
Brii Agreement | Brii Bio Parent | Vir 2218 | VIR-3434
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Option exercise fee received							20,000,000.0
Brii Agreement | Brii Bio
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Range of royalty payment to be paid					mid-teens to high-twenties
Royalty payment obligation expiration period after first commercial sales					10 years
Deferred revenue, noncurrent																				1,500,000
Brii Agreement | Brii Bio | Development Programs Exercised by Brii | VIR-3434
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Regulatory milestone payment to be received							30,000,000.0
Maximum sales milestone to be received							$ 175,000,000.0
Alnylam Agreement | Alnylam Pharmaceuticals Inc
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of common stock, shares | shares									1,111,111
Written notice period to terminate licensed program for uncured material breach														60 days
Written Notice period to terminate licensed program if under challenge														30 days
Royalty payment obligation expiration period after first commercial sales																					10 years
Maximum shares to be issued | shares						1,111,111								1,111,111
Estimated fair value of the derivative liability									$ 29,200,000									$ 29,200,000
Milestone payments paid																	$ 15,000,000.0	$ 15,000,000.0
Expenses incurred under agreement																				1,400,000	$ 11,200,000	11,500,000
Written notice period for termination of licensed program														90 days
Written notice period to terminate licensed program for payment breach														30 days
Alnylam Agreement | Alnylam Pharmaceuticals Inc | First siRNA Product HBV
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Range of tiered royalties to pay on net sales of products						The Company may also be required to pay Alnylam tiered royalties at percentages ranging from the low double-digits to mid-teens on annual net sales of HBV products, and tiered royalties at percentages ranging from the high single-digits to the sub-teen double-digits on annual net sales of licensed infectious disease products, in each case subject to specified reductions and offsets.								low double-digits to mid-teens
Maximum milestone payment for achievement of specified milestones														$ 190,000,000.0
Maximum aggregate sales milestone payment														$ 250,000,000.0
Alnylam Agreement | Alnylam Pharmaceuticals Inc | Each Infectious Disease siRNA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Range of tiered royalties to pay on net sales of products														high single-digits to the sub-teen double-digits
Maximum milestone payment for achievement of specified milestones														$ 115,000,000.0
Maximum sales milestone payment														$ 100,000,000.0
Rockefeller Agreement | Rockefeller
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Termination description												The Company has the right to terminate the Rockefeller Agreement in its entirety, or in part, for any reason on 60 days’ written notice to Rockefeller. Rockefeller may terminate the Rockefeller Agreement on 90 days’ written notice for the Company’s uncured material breach, or if the Company challenges the validity or enforceability of any of the licensed patents, or immediately in the event of the Company’s insolvency. Rockefeller may also terminate the Rockefeller Agreement if the Company ceases to carry on business with respect to the rights granted to the Company under the Rockefeller Agreement.
Written notice period to terminate agreement by company												60 days
Annual License Maintenance Fees												$ 1,000,000.0
Written notice period to terminate agreement by counterparty												90 days
Royalty obligation period from date of first commercial sale												12 years
Research and development expense under license agreement																				$ 1,300,000	4,700,000	$ 1,300,000
Rockefeller Agreement | Rockefeller | Infectious Disease Product
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum aggregate milestone payment for achievement of specified milestones												$ 80,300,000
Rockefeller Agreement | Rockefeller | Infectious Disease Product [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum number of products covered against milestone payment | Product												6
MedImmune Agreement | Influenza A and Influenza B
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalties payment range on net sales of licensed product											mid-single-digits to sub-teen double-digits
MedImmune Agreement | MedImmune
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of antibodies to develop | Antibodies											2
MedImmune Agreement | MedImmune | Influenza A and Influenza B
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Termination description											The Company may terminate the MedImmune Agreement in its entirety or on a product-by-product basis, for convenience, upon 120 days’ notice. Either party may terminate the MedImmune Agreement for cause for the other party’s uncured material breach on 60 days’ notice or immediately in the event of bankruptcy of the other party. Additionally, MedImmune may terminate the MedImmune Agreement for cause on 30 days’ written notice if the Company challenges the validity or enforceability of the patents to which the Company has obtained a license under the MedImmune Agreement.
Written notice period to terminate licensed program for uncured material breach											60 days
Maximum aggregate milestone payment for achievement of specified milestones											$ 331,500,000
Written notice period for termination of licensed program											120 days
Written Notice period to terminate licensed program if under challenges											30 days
2019 Xencor Agreement | Xencor | HBV Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum aggregate milestone payments										$ 77,800,000
2019 Xencor Agreement | Xencor | Influenza A Research Programs
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum aggregate milestone payments										$ 77,800,000
2019 Xencor Agreement | Xencor | Influenza A and HBV Research Programs
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalties payment range on net sales of licensed product										low- to mid-single-digits
Maximum aggregate milestone payments										$ 155,500,000
Maximum aggregate development and regulatory milestone payments										17,800,000
Maximum aggregate commercial sales milestone payments										$ 60,000,000.0
2020 Xencor Agreement | Xencor
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalties payment expiration period																				12 years
Royalties based on net sales of licensed products																				mid-single-digits
Cost of revenue																				$ 114,500,000	$ 52,700,000
2019 and 2020 Xencor Agreement member | Xencor
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Termination description																				The Company may terminate each agreement in its entirety, or on a target-by-target basis, for convenience upon 60 days’ written notice. Either party may terminate each agreement for the other party’s uncured material breach upon 60 days’ written notice (or 30 days in the case of non-payment) or in the event of bankruptcy of the other party immediately upon written notice. Xencor may terminate each agreement immediately upon written notice if the Company challenges, or upon 30 days’ written notice if any of the Company’s sublicensees challenge, the validity or enforceability of any patent licensed to the Company under each respective agreement.
Written notice period for uncured material breach																				60 days
Written notice period for termination of licensed program																				60 days
Written Notice period to terminate licensed program if under challenges																				30 days
Written notice period to terminate licensed program for failure to make payment																				30 days